476040.Kq
The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
The company's capital structure is characterized by a debt-to-equity ratio of 0.29, indicating a relatively low level of leverage. The liquidity position is marked by a current ratio of 2.66, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents amount to 5,237,763,440 KRW, which is less than its long-term debt of 7,053,981,060 KRW, resulting in a net cash position that is negative after subtracting total debt.
Profitability metrics show a challenging financial position, with a return on equity of -0.6231 and a return on assets of -0.4132, both significantly below the industry median. The company reported a net loss of 15,368,102,910 KRW and an operating loss of 16,102,046,930 KRW, indicating a lack of operational profitability. The price-to-book ratio of 4.51 suggests that the market is valuing the company's equity at a premium relative to its book value, despite the negative returns.
The company's revenue is primarily concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with the company's revenue streams, as it is highly dependent on the performance of its primary business segment. The absence of detailed segment and geographic data limits the ability to assess the company's exposure to different markets.
The company's growth trajectory is negative, with a significant decline in revenue and profitability. The operating cash flow is negative at -13,989,498,800 KRW, and the free cash flow is also negative at -16,258,372,590 KRW. These figures indicate that the company is not generating sufficient cash from operations to sustain its activities, let alone fund growth initiatives. The capital expenditure of -1,964,158,930 KRW further highlights the company's financial constraints.
The risk assessment indicates a medium level of liquidity risk, with the company's cash and equivalents being less than its long-term debt. The dilution risk is assessed as low, but the company's negative net income and operating cash flow suggest potential future dilution pressures. The key flag of negative net cash after subtracting total debt underscores the company's liquidity challenges.
Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The absence of recent transcripts or filings limits the ability to assess the company's current strategic direction and management's outlook.
- The company is experiencing significant financial losses, with a net loss of 15,368,102,910 KRW and an operating loss of 16,102,046,930 KRW.
- The company's liquidity position is weak, with a negative net cash position after subtracting total debt.
- The company's profitability metrics are below the industry median, with a return on equity of -0.6231 and a return on assets of -0.4132.
- The company's growth trajectory is negative, with declining revenue and profitability.
- The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 476040.KQ Market data — financials · 2026-05-26